Table 1.
Clinical characteristics of 50 patients with t-MN treated with azacitidine
| Patient Characteristics | n ( range) |
|---|---|
|
Median age (years, median, range) |
66 (37–84) |
|
Sex (M/F) |
28/22 |
|
ECOG PS |
|
| 0–1 |
46 |
| 2-3 |
4 |
|
Type of t-MDS/AML according to the WHO |
|
| - AML: |
16 |
| BM-blasts 20-29% |
5 |
| BM-blasts ≥30% |
11 |
| - MDS: |
34 |
| RCMD |
12 |
| RAEB1 |
9 |
| RAEB 2 |
13 |
|
Primary malignancy : |
|
| - Lymphoproliferative disease |
19 |
| - Multiple myeloma |
3 |
| - Chronic myeloproliferative disease |
5 |
| - Breast cancer |
6 |
| - Urogenital |
9 |
| - Other |
8 |
|
Treatment for Primary Malignancy: |
|
| - Chemotherapy |
27 |
| - Radiotherapy |
9 |
| - RTx + CTx |
14 |
|
Median latency between primary cytotoxic therapy and t-MN diagnosis (years) |
6.1 (0.2-29.8) |
|
Median value at diagnosis (range): |
|
| - White blood cell counts (109 /L) |
2.6 (0.1-26) |
| - Platelets (109 /L) |
69.5 (5–395) |
| - Bone Marrow blasts (%) |
13 (1–90) |
| - LDH (UI/L) |
403 (130–2498) |
|
Median interval between t-MN diagnosis and AZA treatment (months) |
1.8 (0–39) |
|
Response to treatment: |
|
|
- Overall response: |
20 (42%) |
| - CR |
10 (21%) |
| - PR |
2 (4.2%) |
| - HI |
8 (16.7%) |
| - Stable disease |
15 (31%) |
| - Progression |
13 (27%) |
| - Not evaluable |
2 |
| Median cycles number for response | 3 (range 1–6) |
Legend: RTx: Radiotherapy ; CTx: Chemotherapy; CR: complete remission; PR: partial remission; HI: hematological improvement.